BioPhenoMA Inc. has developed an innovative platform for the detection and quantification of ultra-low concentrations of proteins, which is crucial for advancing biomedical research. Their proprietary technology, known as TN-cyclon™ (Enzyme Cycling Method), allows for ultra-sensitive protein quantification at levels below 1 pg/mL. This method is designed to be user-friendly, requiring no specialized equipment beyond what is typically available in standard laboratory settings. By enabling the detection of minute protein quantities, BioPhenoMA aims to bridge the gap in understanding the mechanisms of biological phenomena, which are largely driven by proteins.

In addition to TN-cyclon™, the company recognizes the importance of integrating emerging technologies in protein analysis, such as cryo-electron microscopy for three-dimensional structural analysis and AI systems for rapid protein shape prediction. While traditional mass spectrometry has made significant strides in protein detection, it often involves lengthy preprocessing and requires large, complex equipment. BioPhenoMA's approach seeks to democratize protein detection, making it more accessible and efficient for researchers, thereby contributing to the broader field of biomedical science and the development of pharmaceuticals and diagnostic tools.

Japan

Providing high-sensitivity quantification services for ultra-trace proteins, we will support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

1-22-3 Nishiwaseda, Waseda University EntrepreneurshipCenter, Shinjuku, Tokyo 169-0051, JP

BioPhenoMA Inc.

Company Details